Raymond James Lowers AaiPharma to 'Market Perform'

Analyst Michael Krensavage says new data shows declining prescriptions for the newly acquired Darvon line.

Raymond James downgraded aaiPharma (AAII ) to market perform from strong buy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.